Operating loss at KRW 4.1 billion, down 36.3%

NGeneBio more than quadrupled its revenue through the third quarter of this year, driven by the addition of its pharmaceutical distribution business and growth in its precision diagnostics business. Its operating loss also narrowed compared with the same period last year.

NGeneBio Revenue Up 308% Through Q3; Operating Loss Narrows View original image

On November 16, NGeneBio said its consolidated revenue for the first three quarters totaled KRW 37.8 billion, up 308.3% from KRW 9.3 billion in the same period a year earlier. Its cumulative operating loss for the period narrowed 36.3% to KRW 4.1 billion. In the third quarter alone, revenue rose 147.5% to KRW 13.4 billion, while the operating loss decreased 20.5% to KRW 1.3 billion.


The increase in revenue was attributed to the addition of the pharmaceutical distribution business and steady growth in the bio division. The division's revenue for the first three quarters reached KRW 4.1 billion, up 62.1% from a year earlier. Domestic revenue grew 75.8%, led by the division's core next-generation sequencing (NGS) precision diagnostics business, driving its overall growth.


By product, precision diagnostic panels for blood cancers posted the most notable growth. Revenue from the division's two blood cancer diagnostic panels for the first three quarters rose 38.8% from the same period last year. Sales of its blood cancer diagnostic products overseas grew faster than domestic sales, also contributing to the division's growth.


NGeneBio plans to expand supplies of its "NGS Total Solution," which combines NGS diagnostic panels, analysis software and testing equipment, and broaden its partnerships with medical institutions. The company is also diversifying its revenue sources to improve its financial structure. Earlier this month, it decided on a KRW 8 billion rights offering to its largest shareholder and the acquisition of solar power company Solar AM Holdings.



Lee Gyeongnam, CEO of NGeneBio, said, "As growth in our existing bio business continues and the pharmaceutical distribution business contributes to revenue, the company's business structure is also changing. In precision diagnostics, we will expand product sales and partnerships with medical institutions, while carefully evaluating the profitability of investments in new businesses to improve our performance over the medium to long term and enhance corporate value."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing